After the withdrawal of immunosuppressive treatment, the initial management of PML involved plasma exchange in most natalizumab-treated patients (79.7%) and in some S1P-RM–treated patients (25%, p < 0.001), although this technique does not remove S1P-RM (Table 2). This evidence concerns the gene MBTPS1 and progressive multifocal leukoencephalopathy.